导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.55% | 2186/3712 |
| 近一周 | -1.28% | 1473/4228 |
| 近一月 | -1.08% | 812/4196 |
| 近一季 | 0.26% | 774/4044 |
| 近半年 | 0.46% | 1010/3824 |
| 近一年 | 2.29% | 1786/3446 |
| 近两年 | 41.03% | 1493/2399 |
| 近三年 | 27.71% | 916/1802 |
| 成立以来 | 31.12% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.06% 4019/4961 |
7.80% 2665/5312 |
- - |
- - |
| 2025 | 17.28% 2391/4813 |
-0.46% 2259/3635 |
3.10% 1169/4076 |
11.54% 3150/4524 |
2.45% 947/4813 |
| 2024 | 19.05% 560/3463 |
3.70% 523/2808 |
0.03% 652/3014 |
17.31% 1213/3129 |
-2.17% 1985/3463 |
| 2023 | -8.34% 1001/2656 |
1.01% 1659/2280 |
-4.37% 1153/2385 |
1.84% 271/2515 |
-6.83% 1938/2655 |
| 2022 | -16.81% 516/2207 |
-11.39% 506/1919 |
6.65% 644/2016 |
-13.35% 889/2113 |
1.59% 1210/2208 |
| 2021 | -6.67% 1017/1822 |
-2.74% 697/1255 |
0.61% 1091/1330 |
-6.94% 1009/1466 |
2.49% 578/1822 |
| 2020 | 26.57% 603/1250 |
-11.15% 820/1028 |
11.55% 725/1067 |
12.75% 366/1164 |
13.26% 376/1184 |
| 2019 | 38.07% 320/1092 |
23.60% 545/754 |
4.42% 29/804 |
0.78% 469/850 |
6.15% 650/918 |
| 2018 | -17.38% 130/834 |
- - |
- - |
- - |
-12.12% 404/691 |
| 2017 | 30.41% 58/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.33% 140/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时上证50ETF VS. 长安沪深300非周期A(740101) |